AtriCure (ATRC) Stock Forecast & Price Target

AtriCure is supported by a compelling combination of near-term clinical catalysts and a large underpenetrated addressable market, with BoxX-NoAF expected to read out positively and potentially unlock a POAF risk-reduction label for EnCompass and AtriClip. The company already has strong commercial infrastructure, well-characterized safety profiles, and meaningful reimbursement, while the new STS quality measure could lift U.S. open ablation penetration from about 31% to 45% and expand the roughly $470M domestic pre-op AF market. Financially, the case implies mid-teens domestic open ablation growth through 2030, about 14.6% adjusted EBITDA margin in 2026E, and roughly 130 bps of additional margin expansion in 2027E as trial investment fades and leverage improves.

AtriCure is facing a tougher fundamental setup because the 2026 STS Annual Meeting’s new quality measure elevates scrutiny on how often eligible cardiac surgery patients with pre-operative AF receive ablation and/or LAA treatment, yet reported ablation-specific rates remain well below total AF-related treatment rates. While the company still benefits from AtriClip, Open Ablation, and Cryo Nerve Block momentum, its reliance on continued training, open-surgery volume growth, and physician adoption leaves execution highly dependent on factors that can slow quickly, including sales force attrition, competitive pressure, and share shift away from surgical ablation. The stated valuation support of about 3.5x 12-24 month revenue implies optimism, but the negative outlook is grounded in meaningful risks from decelerating open-heart surgery volumes, volatile OUS results, and litigation.